CRISPR Therapeutics Hits Day Low of $64.80 Amid Price Pressure

CRISPR Therapeutics AG experienced a significant decline today, with the stock dropping by 8.02% and hitting an intraday low of USD 64.80. This performance stands in contrast to the S&P 500, which remained unchanged at 0.0% for the day. Over the past week, CRISPR has seen a decrease of 7.38%, while its monthly performance shows a modest gain of 7.12%. However, the stock has demonstrated a strong yearly performance, up 38.47%, and a year-to-date increase of 69.0%.
Despite these positive yearly metrics, the company faces challenges reflected in its financial indicators. CRISPR Therapeutics has reported negative results for the last four consecutive quarters, with net sales declining by 81.48% and a net profit of -285.6 million USD, marking an 85.88% decrease. The company's return on equity stands at a low 3.15%, indicating limited profitability relative to shareholder funds. Additionally, the stock is trading at a price-to-book ratio of 2.88, amidst a backdrop of negative EBITDA and a debt-to-equity ratio of -1.00.